Stay updated on Pembrolizumab with Radiotherapy in CTCL Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with Radiotherapy in CTCL Clinical Trial page.

Latest updates to the Pembrolizumab with Radiotherapy in CTCL Clinical Trial page
- Check6 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3 on the page, indicating a minor update to revision history that does not affect the trial data or core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page now shows Revision: v3.3.3 in place of Revision: v3.3.2, and the HHS Vulnerability Disclosure link was removed.SummaryDifference0.1%

- Check55 days agoChange DetectedAdded a note that PubMed publications are automatically populated for this study and updated the page revision from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check63 days agoChange DetectedRemoved the banner about government funding status and potential delays in updates. The study details, eligibility criteria, and listed locations remain unchanged.SummaryDifference0.3%

- Check77 days agoChange DetectedBoth screenshots show only minor UI/formatting adjustments; there are no changes to the study design, eligibility criteria, primary/secondary outcomes, or participating locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check106 days agoChange DetectedCore content updated with an operating-status notice and a new topic/term added; the version is updated from v3.1.0 to v3.2.0, indicating a new release. There are no conflicting deletions that negate these additions.SummaryDifference3%

Stay in the know with updates to Pembrolizumab with Radiotherapy in CTCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Radiotherapy in CTCL Clinical Trial page.